Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G CLELAND

Showing results (641-650 of 663) with videos related to

Pageof 67
Sort By:
European Journal of Heart Failure|February 23, 2021
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trialNinian N Lang, Faheem A Ahmad, John G Cleland, et al.
European Journal of Heart Failure|November 7, 2019
Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targetsThong H Cao, Donald J L Jones, Adriaan A Voors, et al.
European Journal of Heart Failure|December 19, 2017
Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failureJohanna Elisabeth Emmens, Donald J L Jones, Thong H Cao, et al.
Circulation. Heart Failure|May 16, 2023
Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart StudyNicolas Girerd, Daniel Levy, Kevin Duarte, et al.
Clinical Proteomics|November 10, 2018
Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failureThong Huy Cao, Donald J L Jones, Paulene A Quinn, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 6, 2019
Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillationIfy R Mordi, Bernadet T Santema, Mariëlle Kloosterman, et al.
Journal of Internal Medicine|May 7, 2020
Tumour biomarkers: association with heart failure outcomesC Shi, H H van der Wal, H H W Silljé, et al.
European Journal of Heart Failure|December 19, 2020
Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHFBeth A Davison, Stefanie Senger, Iziah E Sama, et al.
JACC. Heart Failure|November 29, 2020
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF StudyG Michael Felker, John J V McMurray, John G Cleland, et al.
European Journal of Heart Failure|June 20, 2020
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trialAdriaan A Voors, Jean-François Tamby, John G Cleland, et al.
Pageof 67

Showing results (641-650 of 663) with videos related to

Sort By:
Pageof 67
European Journal of Heart Failure|February 23, 2021
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trialNinian N Lang, Faheem A Ahmad, John G Cleland, et al.
European Journal of Heart Failure|November 7, 2019
Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targetsThong H Cao, Donald J L Jones, Adriaan A Voors, et al.
European Journal of Heart Failure|December 19, 2017
Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failureJohanna Elisabeth Emmens, Donald J L Jones, Thong H Cao, et al.
Circulation. Heart Failure|May 16, 2023
Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart StudyNicolas Girerd, Daniel Levy, Kevin Duarte, et al.
Clinical Proteomics|November 10, 2018
Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failureThong Huy Cao, Donald J L Jones, Paulene A Quinn, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 6, 2019
Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillationIfy R Mordi, Bernadet T Santema, Mariëlle Kloosterman, et al.
Journal of Internal Medicine|May 7, 2020
Tumour biomarkers: association with heart failure outcomesC Shi, H H van der Wal, H H W Silljé, et al.
European Journal of Heart Failure|December 19, 2020
Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHFBeth A Davison, Stefanie Senger, Iziah E Sama, et al.
JACC. Heart Failure|November 29, 2020
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF StudyG Michael Felker, John J V McMurray, John G Cleland, et al.
European Journal of Heart Failure|June 20, 2020
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trialAdriaan A Voors, Jean-François Tamby, John G Cleland, et al.
Pageof 67